Retrospective Cohort Study
Copyright ©The Author(s) 2020.
World J Hepatol. Sep 27, 2020; 12(9): 619-627
Published online Sep 27, 2020. doi: 10.4254/wjh.v12.i9.619
Table 1 Charlson Co-morbidity index
Co-morbid conditioncCCI weightsuCCI weights
Myocardial infarction10
Congestive heart failure12
Peripheral vascular disease10
Cerebrovascular disease10
Dementia12
Chronic obstructive pulmonary disease11
Connective tissue disorder11
Peptic ulcer disease10
Mild liver disease12
Diabetes without complication10
Diabetes with complication21
Hemiplegia or paraplegia22
Chronic kidney disease stage III21
Any malignancy without metastasis22
Leukemia2
Lymphoma2
Moderate or severe liver disease34
Metastatic tumor66
AIDS64
Maximum score3324
Table 2 Demographic and baseline characteristics of the study population
VariableStudy population (n = 130)
Age, yr, median (IQR)62 (48, 73)
Females59 (45.4)
Body mass index, kg/m2, median (IQR)28.7 (26, 36)
Smoking38 (29.2)
Alcohol30 (23.1)
Diarrhea34 (26.2)
Nausea32 (24.6)
Abdominal pain21 (16.2)
Anorexia34 (26.2)
Other gastro-intestinal symptoms137 (28.5)
X-ray findings287 (66.9)
Hypertension69 (53.1)
Admitted to ICU58 (44.6)
On ventilator43 (33.1)
Age-adjusted Charlson Index, median (IQR)3.5 (1, 6)
On medications with gastro-intestinal side-effects46 (35.4)
Death28 (21.5)
Lactic Acid, mean (SD), n = 971.7 (1.4)
Lactic acid dehydrogenase, mean (SD), n = 92424 (182.6)
D-dimer, median (IQR), n = 1051.7 (0.9, 3.7)
Alanine aminotransferase, IU/L, median (IQR)29 (16, 53)
Aspartate aminotransferase, IU/L, median (IQR)39 (23, 68)
Alkaline phosphatase, IU/L, median (IQR)77 (60, 115)
Total bilirubin, mean (SD)0.4 (0.3)
Direct bilirubin, mean (SD), n = 920.2 (0.1)
Albumin, g/dL, mean (SD)3.2 (0.8)
Prothrombin time, seconds, mean (SD), n = 8116.9 (8.1)
Table 3 Characteristics of those with and without transaminitis
Transaminitis (n = 73)No transaminitis (n = 57)P value
Age, yr, median (IQR)63 (48, 72)62 (48, 76)0.9
Females31 (42.5)28 (49.1)0.4
Body mass index, kg/m2, median (IQR)30.2 (26.5, 36.8)27.3 (24.5, 33.2)0.04
Smoking19 (26)19 (33.3)0.4
Alcohol20 (27.4)10 (17.5)0.2
Diarrhea24 (32.9)10 (17.5)0.05
Nausea18 (24.7)14 (24.6)1.0
Abdominal pain11 (15.1)10 (17.5)0.7
Anorexia19 (26)15 (26.3)1.0
Other gastro-intestinal symptoms119 (26)18 (31.6)0.5
X-ray findings255 (75.3)32 (56.1)0.02
Hypertension38 (52.1)31 (54.4)0.8
Age-adjusted Charlson Index, median (IQR)3 (1, 6)4 (1, 6)0.7
On ventilator31 (42.5)12 (21.1)0.01
Admitted to intensive care unit39 (53.4)19 (33.3)0.02
On medications with GI side-effects26 (35.6)20 (35.1)1.0
Alanine aminotransferase, IU/L, median (IQR)48 (34, 84)15 (10, 20)< 0.001
Aspartate aminotransferase, IU/L, median (IQR)66 (42, 100)20 (14, 26)< 0.001
Alkaline phosphatase, IU/L, median (IQR)97 (66, 124)70 (56, 92)< 0.001
Total bilirubin, mean (SD)0.6 (0.3)0.4 (0.2)< 0.001
Albumin, g/dL, mean (SD)3.0 (0.8)3.4 (0.7)0.01
Table 4 Multivariable logistic model for death in patients with and without transaminitis
VariableModel 1
Model 2
Model 3
OR (95%CI)P valueOR (95%CI)P valueOR (95%CI)P value
Transaminitis2.9 (1.1-7.4)0.033.1 (1.2-8.0)0.023.4 (1.2-10.1)0.03
Gender, reference females-0.5 (0.2-1.2)0.5 (0.2-1.4)
AACI above median score of 3.5--12.9 (3.5-48.4)
Admission to intensive care unit--3.6 (1.2-10.4)